HilleVax, Inc. (NASDAQ:HLVX) Shares Sold by Qiming U.S. Ventures Management LLC

Qiming U.S. Ventures Management LLC trimmed its stake in shares of HilleVax, Inc. (NASDAQ:HLVX - Free Report) by 33.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 372,615 shares of the company's stock after selling 186,308 shares during the quarter. HilleVax makes up 1.5% of Qiming U.S. Ventures Management LLC's holdings, making the stock its 5th biggest holding. Qiming U.S. Ventures Management LLC owned about 0.75% of HilleVax worth $771,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Barclays PLC raised its position in shares of HilleVax by 255.6% in the third quarter. Barclays PLC now owns 42,033 shares of the company's stock valued at $74,000 after purchasing an additional 30,213 shares during the period. Braidwell LP purchased a new position in shares of HilleVax during the 3rd quarter valued at about $1,873,000. GSA Capital Partners LLP purchased a new stake in shares of HilleVax in the 3rd quarter valued at $126,000. Jane Street Group LLC grew its stake in shares of HilleVax by 81.7% during the third quarter. Jane Street Group LLC now owns 79,039 shares of the company's stock valued at $139,000 after buying an additional 35,546 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of HilleVax by 31.7% during the second quarter. Dimensional Fund Advisors LP now owns 152,602 shares of the company's stock valued at $2,204,000 after purchasing an additional 36,690 shares during the period. Institutional investors and hedge funds own 86.42% of the company's stock.

HilleVax Price Performance

NASDAQ:HLVX remained flat at $1.74 during mid-day trading on Wednesday. The company had a trading volume of 194,156 shares, compared to its average volume of 216,998. The firm has a market cap of $86.67 million, a price-to-earnings ratio of -0.56 and a beta of 0.74. The firm's 50-day moving average is $1.95 and its 200 day moving average is $1.87. HilleVax, Inc. has a 52 week low of $1.55 and a 52 week high of $20.22.

HilleVax Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.